Shares in the antibody discovery platform developer, advancing UBC research, opened at more than three times their IPO price to net it a valuation topping $15bn.

ETH Zurich-founded HeiQ chose the London Stock Exchange for its listing having posted a $10.9m operating profit for the first half of the year.

Berkeley Catalyst Fund-backed gene therapy developer 4D Molecular Therapeutics withdrew its last attempt in July.

Chronic illness drug developer Sigilon Therapeutics, co-founded by MIT and UIC researchers, has filed to go public after raising almost $200m in funding.

The University of Oslo sensor software spinout has started trading on the Merkur Market, part of the Oslo Stock Exchange.

NTU spinout Nanofilm Technologies has seemingly filed a draft prospectus with a view of listing on the domestic Singapore Stock Exchange.

Codiak – based on research at Gothenburg and MD Anderson Cancer Center – has succeeded in going public after previously cancelling plans.

MIT's cancer drug developer Kronos Bio floated above its range in an upsized offering and saw its shares soar in price post-IPO.

Galecto has filed to go public nine years after being founded in Sweden to commercialise research from Lund and Edinburgh universities.

MIT's cancer therapy developer has set terms for an offering that will raise more than $185m if it floats at the top of its range.